Skip to content

The effect of scarring moxibusion on blood in patients with gastric cancer

Study on the immune synergistic effect of grain moxibustion assisted cell immunotherapy in the treatment of advanced gastric cancer—the influence on the pivotal regulation of lymphocytes and the blood transcriptome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008097
Enrollment
Unknown
Registered
2016-03-14
Start date
2016-06-08
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

moxibusion treatment group:scarring moxibusion
Grain moxibustion combined with CIK group:Grain moxibustion combined with CIK treatment
CIK group:CIK treatment
Blank control group:Don't do anything with normal people

Sponsors

Peoples Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1. having been diagnosed with gastric cancer by specialists according to histopathologic examination; 2. having completed the lobectomy; 3. having finished the adjuvant chemotherapy or radiotherapy after the surgery; 4. joining in the study of their own accord.

Exclusion criteria

Exclusion criteria: 1. patients with uncertain diagnosis; 2. medically inoperable patients; 3. patients during the process of chemotherapy or radiotherapy; 4. patients with advanced disease, such as malignant pleural effusion and involvement or distant metastasis; 5. diabetic patients and patients with dermatosis or other diseases affecting the kin to heal; 6. disagreeing to join in the trial.

Design outcomes

Primary

MeasureTime frame
White blood cells;lymphocyte;neutrophil;Platelet;CD19+;CD28+;CD8+/CD28+;CD8+/CD28-;CD3+;CD3+/HLA-DR+;CD3+/HR-DR-;CD-/CD16+56+;CD4+CD25+;CD4+/CD29+;CD4+/CD45RA+;CD4+/CD45RO+;Differential expression analysis of genes;GO and KEGG function notes;rng-seq analysis;

Secondary

MeasureTime frame
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactLing Guan

Peoples Liberation Army General Hospital

guanling@sina.com+86 13520575830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026